Research
Valbenazine for Tardive Dyskinesia Tied to Less Antipsychotic Drop-Off
The Brief
- Starting valbenazine (Ingrezza) to treat tardive dyskinesia might reduce antipsychotic discontinuation in patients newly diagnosed with the side effect.
- The finding comes from a retrospective cohort study of Medicare claims, as reported by MedPage Today.
Why it matters
Clinicians managing antipsychotic-treated patients with tardive dyskinesia may weigh this association when choosing treatment, though a retrospective claims study cannot establish cause and effect.
Who’s affected
- psychiatrists and clinicians treating tardive dyskinesia
- patients taking antipsychotic medication
- #tardive dyskinesia
- #valbenazine
- #antipsychotics
- #medicare
- #retrospective study
(MedPage Today) -- Starting valbenazine (Ingrezza) to treat tardive dyskinesia might reduce antipsychotic discontinuation in patients newly diagnosed with the side effect, a retrospective cohort study of Medicare claims indicated. Among patients...